Navigation Links
Align Technology Names Dana C. Cambra as VP, Research & Development
Date:5/19/2008

SANTA CLARA, Calif., May 19 /PRNewswire-FirstCall/ -- Align Technology, Inc. (Nasdaq: ALGN), today announced that it has hired Dana C. Cambra as vice president of research and development, effective June 16. Mr. Cambra will report directly to Align President and Chief Executive Officer, Thomas M. Prescott and lead the Company's research and development initiatives.

"Product innovation is Align's highest priority and we are pleased to have Dana on board to lead the team responsible for developing and executing our research initiatives and product roadmap," said Thomas M. Prescott, Align president and CEO. "Dana's extensive experience in medical technology and software development will be of tremendous value to Align as we continue our history of innovation and build the next generation of Invisalign products."

Innovation has been a hallmark of Mr. Cambra's career. As a member of the management and technical teams at Acuson Corporation, now a Siemens Company, he was instrumental in the development of the Sequoia Medical Diagnostic Ultrasound system, a breakthrough in high-resolution ultrasound products that has generated more than $4 billion in revenue.

More recently, Mr. Cambra served as senior vice president, research and development for Pharsight Corporation, a leading provider of simulation and modeling software for pharmaceutical and biotechnology companies. Prior to his role at Pharsight, Mr. Cambra was vice president, engineering at Stentor Inc. and the Phillips Global PACS business unit, an industry leader in providing medical informatics solutions. Earlier roles included senior engineering and operations positions at Visto, where he led development of communications solutions for the first Handspring/Palm Treo
'/>"/>

SOURCE Align Technology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. US Oncology Applauds Journal of Clinical Oncology Study Highlighting Value of PET Scans for Cancer Patients With Various Types of Malignancies
2. NUCRYST Announces Management Realignment and R&D Portfolio Change
3. New regulatory circuit identified for aggressive, malignant brain tumor
4. Malignant tumor or benign cyst?
5. Is Cancer Community in Alignment About Cure and Costs? NCCN Conference Panel Asks
6. Protein in Human Embryonic Stem Cells Controls Malignant Tumor Cells
7. Protein in embryonic stem cells control malignant tumor cells
8. ULLICO Casualty Group Aligns with Hudson Insurance Company to Offer Fiduciary and Union Liability Insurance
9. Alessi Skin Care Aligns With Celebrity Socialite Fabian Basabe to Raise Awareness for Their Face Forward Campaign
10. InterComponentWare Inc. Aligns with the Center for Health Transformation
11. Align Technology Executives to Present at Upcoming Financial Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Pharmacy Technician Employment Increasing Up to 32% By 2016 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4Binge Drinking Not Just a Rite of the Young 62247 1Binge Drinking Not Just a Rite of the Young 62247 2Healing from the Inside Out 3A Compelling New Book Explores the Intricate Connection between Body Soul and Better Health 62245 1Healing from the Inside Out 3A Compelling New Book Explores the Intricate Connection between Body Soul and Better Health 62245 2Baxa to Sponsor ASHP Midday Symposium 3A Creating a Culture of Safety in Pharmacy A Panel Discussion on Lessons Learned 62243 1Baxa to Sponsor ASHP Midday Symposium 3A Creating a Culture of Safety in Pharmacy A Panel Discussion on Lessons Learned 62243 2Baxa to Sponsor ASHP Midday Symposium 3A Creating a Culture of Safety in Pharmacy A Panel Discussion on Lessons Learned 62243 3
Other Medicine Technology:Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 2Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 4Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 5Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 6Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 7Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 2Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 3Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 4Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 5Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 6Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 7Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 8